Sign in
CompletedPhase 1

Cannabinoids for Pain Management and Neuroprotection From Concussion

Key facts

Who runs it
University of Regina
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
34 people enrolled
Started
15 Feb 2024
Ended
30 Nov 2024
Type of study
Interventional
Treatments tested
  • Cannabis/Hemp Isolate Extract
Record updated
6 May 2026

Who can take part

Age
18 years to 35 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Healthy male adults between 18-35 years of age that compete in contact sport athletics
  • No known cerebrovascular or cardiovascular complications
  • Not habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
  • Agree not to consume any other cannabis or tobacco products while enrolled in the study
  • Agree to list any prescription medications being taken
  • Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests

Who cannot take part

  • Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2 month period without use of cannabis based therapy prior to enrolment in the study)
  • Initiation or dosage change of oral or injected steroids within past 3 months
  • Medically supervised for anxiety, depression, or other neurological conditions
  • Allergy or known intolerance to any of the compounds within the study preparation
  • Inability to attend assessments on a regular basis at the pre-determined times, or failure to take drug on a daily basis
  • Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
  • Female
  • Requirement to travel to the USA during study period; USA laws do not permit cross border with cannabis products
  • Any level of cannabis in blood samples when sampled at the commencement of the study
  • Concussion

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this open-label, placebo-controlled, dosage escalation study is to learn about the safety of a Cannabis/Hemp Isolate Extract in normal healthy adults engaged in elite contact sport competition.

Read full original descriptionShow less

The main question it aims to answer is:

• Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis?

Participants will:

* be given CBD and a placebo. The placebo will be taken for 2 weeks prior to starting the CBD. Participants will start on a low dose of CBD, beginning at 5 mg CBD/kg body mass, which will be increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken; * have blood samples taken to analyse how much CBD is used in the body and for how long it lasts in the body (pharmacokinetics and pharmacodynamics); * have saliva samples collected for genetic analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.

The group in the trial

  • Dose EscalationTreatment being tested

    When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.

    Treatment: Cannabis/Hemp Isolate Extract

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation
Publications
Record updated
6 May 2026